GSK statement on meningitis vaccination in the UK

GSK is delighted to have reached an agreement with the UK's Department of Health that will enable babies in the UK to receive its meningitis B vaccine through the NHS immunisation schedule.

We have moved rapidly to conclude negotiations since we acquired the vaccine from Novartis at the beginning of March.

We believe the agreement we have reached offers fair value for the NHS and allows a reasonable return for GSK to ensure that we can continue to invest in creating new treatments and vaccines.

Suggested Articles

Already developing coronavirus treatments, Takeda struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan

On the heels of last week's deal for 120 million Pfizer-BioNTech shots, Japan has locked down 120 million more vaccines from AstraZeneca.

The pandemic price could be lowered for larger deals, CEO Stephane Bancel said. Pfizer and BioNTech priced 100M doses at $19.50 each for the U.S.